The GLOW trial showed fixed-duration ibrutinib/venetoclax resulted in improved progression-free survival vs chlorambucil/obinutuzumab in some patients with previously untreated chronic lymphocytic leukemia (CLL). An analysis of the trial published by Munir et al in the Journal of Clinical Oncology examined the impact of measurable residual disease (MRD) status on survival outcomes among patients in both treatment groups in GLOW.
